We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mass-Producing Natural Cancer-Killing Cells for Treatment Options for Patients

By LabMedica International staff writers
Posted on 27 Mar 2013
Print article
Scientists reported that they are in the process of generating natural cancer-killing cells in the laboratory in a quantity that could soon make them feasible for treating patients.

Even though the production of human natural killer (NK) cells in the lab from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) has become routine, it has been on a limited scale. But a new study’s findings demonstrate how to increase the number of resulting cells while in addition decreasing the amount of work and time involved in generating them. “NK cells show promise for cancer therapy,” said Dan Kaufman, MD, PhD, of the Stem Cell Institute, University of Minnesota (UM; Minneapolis; USA). “They are part of the innate immune system and exhibit potent antitumor activity without the need for donor matching and prior treatment. Moreover, the derivation of NK cells from pluripotent stem cells could provide an unlimited source of lymphocytes for ‘off-the-shelf’ therapy.”

Dr. Kaufman was the lead investigator of the study that included colleagues from UM as well as from the Integrated Center of Cellular Therapy and Regenerative Medicine, St. Anne’s University Hospital Brno (Brno, Czech Republic); and the University of Texas (Houston, USA). The study’s findings were published March 20, 2013, in the journal STEM CELLS Translational Medicine.

“Human NK cells have been used to treat patients with refractory malignancies, but a major hindrance to expanded use has been the inefficiency of production,” said Anthony Atala, MD, editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine (Winston-Salem, NC, USA). “The current study has identified a two-stage culture system to efficiently produce the cells in a manner more suitable to clinical translation than previous methods.”

Related Links:

Stem Cell Institute, University of Minnesota


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Automatic Nucleic Acid Extractor
GeneRotex 24

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test runs on the cobas liat system (Photo courtesy of Roche)

Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes

The U.S. Centers for Disease Control and Prevention (CDC) has reported that respiratory diseases in the United States reached high levels during the recent autumn and winter seasons, with SARS-CoV-2 leading... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics